To confirm these findings, we measured S100β, DJ-1, UCHL1, Aβ42, t-Tau, p-Tau and α-syn levels in the CSF of an independent, confirmatory cohort II, comprised of 30 early clinical PD patients and 30 controls. This evidence concerns the gene PARK7 and Parkinson disease.